| pubmed-article:18757263 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:18757263 | lifeskim:mentions | umls-concept:C0024312 | lld:lifeskim |
| pubmed-article:18757263 | lifeskim:mentions | umls-concept:C0332281 | lld:lifeskim |
| pubmed-article:18757263 | lifeskim:mentions | umls-concept:C0003234 | lld:lifeskim |
| pubmed-article:18757263 | lifeskim:mentions | umls-concept:C0040808 | lld:lifeskim |
| pubmed-article:18757263 | lifeskim:mentions | umls-concept:C1522673 | lld:lifeskim |
| pubmed-article:18757263 | lifeskim:mentions | umls-concept:C0215136 | lld:lifeskim |
| pubmed-article:18757263 | pubmed:issue | 4 | lld:pubmed |
| pubmed-article:18757263 | pubmed:dateCreated | 2008-9-1 | lld:pubmed |
| pubmed-article:18757263 | pubmed:abstractText | We observed 2 cases of Pneumocystis carinii pneumonia (PCP) occurring in HIV-negative patients during treatment with dose-dense chemotherapy with doxorubicin/cyclophosphamide (AC) followed by paclitaxel (T). These represent the first case reports of PCP occurring during dose-dense chemotherapy for breast cancer. Because lymphocyte depletion is thought to predispose patients to PCP, we explored whether the shortened intervals between cycles during dose-dense chemotherapy might place patients at risk for lymphocyte depletion and thereby a potentially increased risk of opportunistic infection. | lld:pubmed |
| pubmed-article:18757263 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18757263 | pubmed:language | eng | lld:pubmed |
| pubmed-article:18757263 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18757263 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:18757263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18757263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18757263 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:18757263 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:18757263 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:18757263 | pubmed:issn | 1526-8209 | lld:pubmed |
| pubmed-article:18757263 | pubmed:author | pubmed-author:NajitaJulieJ | lld:pubmed |
| pubmed-article:18757263 | pubmed:author | pubmed-author:BursteinHarol... | lld:pubmed |
| pubmed-article:18757263 | pubmed:author | pubmed-author:WinerEric PEP | lld:pubmed |
| pubmed-article:18757263 | pubmed:author | pubmed-author:TolaneySara... | lld:pubmed |
| pubmed-article:18757263 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:18757263 | pubmed:volume | 8 | lld:pubmed |
| pubmed-article:18757263 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:18757263 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:18757263 | pubmed:pagination | 352-6 | lld:pubmed |
| pubmed-article:18757263 | pubmed:dateRevised | 2009-11-30 | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:meshHeading | pubmed-meshheading:18757263... | lld:pubmed |
| pubmed-article:18757263 | pubmed:year | 2008 | lld:pubmed |
| pubmed-article:18757263 | pubmed:articleTitle | Lymphopenia associated with adjuvant anthracycline/ taxane regimens. | lld:pubmed |
| pubmed-article:18757263 | pubmed:affiliation | Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA. stolaney@partners.org | lld:pubmed |
| pubmed-article:18757263 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:18757263 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:18757263 | lld:pubmed |
